Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma.

Xiran HeYang DuZhijie WangXin WangJianchun DuanRui WanJiachen XuPei ZhangDi WangYanhua TianJiefei HanKailun FeiHua BaiJie TianJie Wang

Published in: Journal for immunotherapy of cancer (2021)

We first attempted to optimize chemoimmunotherapy for SQCLC by investigating different combinatorial modes. Compared with the MTD chemotherapy used in current clinical practice, upfront metronomic chemotherapy performed better with subsequent anti-PD-1/PD-L1 mAb treatment. This combination approach is worth investigating in other types of tumors, followed by translation into the clinic in the future.

Keyphrases

squamous cell
locally advanced
clinical practice
primary care
chemotherapy induced
rectal cancer
combination therapy
monoclonal antibody